Reports Q1 revenue $65.7M, consensus $62.47M. Justin Schreiber, chairman and CEO of LifeMD (LFMD), said, “LifeMD had an outstanding first quarter that demonstrated the power of our platform, the need for our services and the accelerated growth trajectory of the business as we achieved our first-ever quarter of GAAP profitability well ahead of expectations. During the quarter we expanded across all service areas, and the performance of our weight management program underscored our success as it is now expected to exceed top- and bottom-line expectations for the full year. The launch of our men’s hormone therapy offering, and recent acceptance of Medicare are also off to strong starts and continue to diversify our already leading telehealth platform.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFMD:
- LifeMD options imply 12.4% move in share price post-earnings
- Is LFMD a Buy, Before Earnings?
- Unusually active option classes on open April 30th
- LifeMD’s Strategic Growth: Buy Rating Backed by Wegovy Integration and Future Offerings
- HIMS Stock Soars 27% as Novo Nordisk (NVO) Expands Wegovy Access to Telehealth
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue